Modelowanie interakcji żywiciel-patogen za pomocą organoidów limfoidalnych
Background:
Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these infections can lead to paralysis and death. Researchers do not know how S. aureus interacts with a person s cells to cause infections in the spine.
Objective:
To learn how S. aureus interacts with cells in the body using tissues from tonsils discarded after standard surgery to remove them.
Eligibility:
People aged 2 years and older who are scheduled to have their tonsils removed.
Design:
Researchers will select participants for the study based on review of their existing medical records, including results of blood tests; any imaging scans, including x-rays; and reports about tissue specimens.
Participants will answer questionnaires about their health and past infections. They can do this online or on paper.
Participants will collect a nasal swab 1 week before their surgery. They will be given a tool that looks like a long cotton swab. They will twirl it around inside their nose. The swab will pick up cells and fluids that will be used for research.
After their surgery, the participant s surgeon will save samples of tonsil tissue. The surgeon will send these tissue samples and the nasal swab to researchers at the NIH.
These tissues and the swab will be used in studies to help researchers understand how S. aureus interacts with cells in the body. They hope these studies will help them find better ways to treat S. aureus infections.
Przegląd badań
Status
Status
Warunki
Warunki
Szczegółowy opis
STUDY DESCRIPTION:
The purpose of this study is to collect tonsil tissues that are routinely discarded after tonsillectomy procedures to develop lymphoid organoid models to evaluate host-pathogen interactions in human health and disease. One such interaction is the human immunotolerance mechanism to the Chemotaxis Inhibitory Protein of S. aureus (CHIPS).
OBJECTIVES:
Primary Objectives:
-Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS.
Secondary Objective:
-Modulate anti-CHIPS IgG4 class switching through variation of primary and costimulatory signals.
ENDPOINTS:
Primary Endpoints:
Differences between the following within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS:
- Immune cell composition.
- Anti-CHIPS antibody levels, including total and subclasses of IgG and their neutralizing capacity.
- Cytokine levels.
- Activation-induced cytidine deaminase (AID) levels.
- Single-cell inference of class switch recombination (sciCSR).
Secondary Endpoints:
Differences between the following modulation of primary and costimulatory signals:
- Immune cell composition.
- Anti-CHIPS antibody levels, including total and subclasses of IgG and their neutralizing capacity.
- Cytokine levels.
- AID levels.
- sciCSR
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Katherine Le, M.D.
- Numer telefonu: (301) 761-7166
- E-mail: katherine.le@nih.gov
Kopia zapasowa kontaktu do badania
- Nazwa: Michael Otto, M.D.
- Numer telefonu: (406) 363-9394
- E-mail: mo112y@nih.gov
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- Rekrutacyjny
- National Institutes of Health Clinical Center
-
Kontakt:
- NIH Clinical Center Office of Patient Recruitment (OPR)
- Numer telefonu: TTY dial 711 800-411-1222
- E-mail: ccopr@nih.gov
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- Rekrutacyjny
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients undergoing tonsillectomy as part of their clinical care at hospitals and pediatric ear nose and throat (ENT) practices in the US will be enrolled.
Opis
- INCLUSION CRITERIA:
To be eligible to participate in this study, an individual must meet all of the following criteria:
- Aged >=2 yrs.
- Undergoing tonsillectomy as part of their clinical care.
- Able to provide informed consent (for ages >=18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages <18 yrs).
- Willing to allow samples and data to be stored and shared for future secondary research.
- Willing to allow future genetic testing on their biospecimens.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Active infection.
- Active tonsilitis.
- Pregnant.
- Diagnosed with an immunosuppressive condition or currently taking immunosuppressive medications.
- Current or past intravenous drug use.
- Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
|---|
|
Tonsillectomy Patients
Patients undergoing tonsillectomy as part of their clinical care |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Immune cell composition
Ramy czasowe: At time of collection
|
Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS. |
At time of collection
|
|
Anti-CHIPS antibody levels, including total and subclasses of IgG and their neutralizing capacity
Ramy czasowe: At time of collection
|
Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS. |
At time of collection
|
|
Cytokine levels
Ramy czasowe: At time of collection
|
Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS. |
At time of collection
|
|
Activation-induced cytidine deaminase (AID) levels
Ramy czasowe: At time of collection
|
Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS. |
At time of collection
|
|
Single-cell inference of class switch recombination (sciCSR)
Ramy czasowe: At time of collection
|
Develop a lymphoid organoid model from discarded human tonsils and determine and compare the human immunologic signatures of primary exposure, within the "antigenic sin" contexts of re-exposure, and with repeated exposures to CHIPS. |
At time of collection
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Immune cell composition
Ramy czasowe: At time of collection
|
Primary signals such as antigen characteristics, and secondary signals such as cytokines have been implicated in class switching to IgG4 but have not been defined with respect to CHIPS. Varying these signals and evaluating: 1) organoid immune cell composition, 2) antibody and 3) cytokines levels, and indicators of class switching such as 4) AID and 5) sciCSR levels, will enable us to evaluate modulation of human immunotolerance to CHIPS. |
At time of collection
|
|
Anti-CHIPS antibody levels, including total and subclasses of IgG and their neutralizing capacity
Ramy czasowe: At time of collection
|
Primary signals such as antigen characteristics, and secondary signals such as cytokines have been implicated in class switching to IgG4 but have not been defined with respect to CHIPS. Varying these signals and evaluating: 1) organoid immune cell composition, 2) antibody and 3) cytokines levels, and indicators of class switching such as 4) AID and 5) sciCSR levels, will enable us to evaluate modulation of human immunotolerance to CHIPS. |
At time of collection
|
|
Cytokine levels
Ramy czasowe: At time of collection
|
Primary signals such as antigen characteristics, and secondary signals such as cytokines have been implicated in class switching to IgG4 but have not been defined with respect to CHIPS. Varying these signals and evaluating: 1) organoid immune cell composition, 2) antibody and 3) cytokines levels, and indicators of class switching such as 4) AID and 5) sciCSR levels, will enable us to evaluate modulation of human immunotolerance to CHIPS. |
At time of collection
|
|
Activation-induced cytidine deaminase (AID) levels
Ramy czasowe: At time of collection
|
Primary signals such as antigen characteristics, and secondary signals such as cytokines have been implicated in class switching to IgG4 but have not been defined with respect to CHIPS. Varying these signals and evaluating: 1) organoid immune cell composition, 2) antibody and 3) cytokines levels, and indicators of class switching such as 4) AID and 5) sciCSR levels, will enable us to evaluate modulation of human immunotolerance to CHIPS. |
At time of collection
|
|
Single-cell inference of class switch recombination (sciCSR)
Ramy czasowe: At time of collection
|
Primary signals such as antigen characteristics, and secondary signals such as cytokines have been implicated in class switching to IgG4 but have not been defined with respect to CHIPS. Varying these signals and evaluating: 1) organoid immune cell composition, 2) antibody and 3) cytokines levels, and indicators of class switching such as 4) AID and 5) sciCSR levels, will enable us to evaluate modulation of human immunotolerance to CHIPS. |
At time of collection
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Michael Otto, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 10002062
- 002062-I
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Experiments will be conducted in groups of 5 to 16 organoids and will be reported according to experimental groups. Participant data will not be reported individually.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .